Clinical Trial: NCT06624059
A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)
Status:
COMPLETEDPhase:
Phase 3| Lead Sponsor: | Hoffmann-La Roche |
| Information Provided By: | Hoffmann-La Roche |
| Last Update Posted: | 2026-08-19 |
Study Overview
Brief Summary
The objective of this study is to explore the safety of alectinib in combination with chemotherapy in participants with resectable NSCLC. Cohort B1 is a phase II cohort that will assess the safety of alectinib in combination with up to four cycles of platinum-based chemotherapy in the adjuvant setting post complete surgical resection.
Official Title
A Phase I-II, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients With Resectable Stage I-III Non-Small Cell Lung Cancer, Selected According to Biomarker Status
Conditions
Non-Small Cell Lung Cancer
Intervention / Treatment
- Drug: Alectinib
- Drug: Cisplatin
- Drug: Carboplatin
- Drug: Pemetrexed
Other Study ID Numbers
- BO43249
Start Date (Actual)
2024-11-18
Primary Completion Date (Actual)
2026-07-31
Study Completion Date (Actual)
2026-07-31
Enrollment (Actual)
11
Study Type
Interventional
Phase
Phase 3
| Lead Sponsor: | Hoffmann-La Roche |
| Information Provided By: | Hoffmann-La Roche |
| Last Update Posted: | 2026-08-19 |
Study Overview
Brief Summary
The objective of this study is to explore the safety of alectinib in combination with chemotherapy in participants with resectable NSCLC. Cohort B1 is a phase II cohort that will assess the safety of alectinib in combination with up to four cycles of platinum-based chemotherapy in the adjuvant setting post complete surgical resection.
Official Title
A Phase I-II, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients With Resectable Stage I-III Non-Small Cell Lung Cancer, Selected According to Biomarker Status
Conditions
Non-Small Cell Lung Cancer
Intervention / Treatment
- Drug: Alectinib
- Drug: Cisplatin
- Drug: Carboplatin
- Drug: Pemetrexed
Other Study ID Numbers
- BO43249
Start Date (Actual)
2024-11-18
Primary Completion Date (Actual)
2026-07-31
Study Completion Date (Actual)
2026-07-31
Enrollment (Actual)
11
Study Type
Interventional
Phase
Phase 3